GeneDx Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- GeneDx reported 3rd quarter 2026 total revenue of $123.1 million, including $110.4 million of exome genome revenue, which was up $10 million sequentially.
- The company reported adjusted gross margin of 72%, adjusted net income of $8.6 million, and more than 32,100 exome and genome tests.
- The blended average reimbursement rate was $3,436, up 5% from $3,258 in the 2nd quarter.
- Adjusted gross margin increased from 69% in Q1 to 70% in Q2 and 72% in Q3, while adjusted net income improved from an $8.2 million loss in Q1 to near breakeven in Q2 and $8.6 million in Q3.
- Accessions grew 28% year over year while reported volume grew 25%, as upfront documentation requirements contributed to cancellations, downgrades, and delayed starts.
- Outpatient genome collection rate was 36% in Q3, up 400 basis points from 32% in Q2; the exome collection rate was approximately 32%, flat with Q2.
- Genome represented 26% of outpatient insurance-based volume, down from 32% in Q2, while 92% of volume was outpatient insurance-based and Medicaid was the largest payer segment at 48%.
- Positive exome policies covered 98% of commercial lives and positive genome coverage covered 88%; Medicaid covered exome in 37 states and genome in 25 states, up from 23 states in Q2.
- Genome cost per test had declined 43% from last year, and GeneDx said it expects further reductions over the next several quarters.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker, Sabrina Dunbar. Investor relations, please go ahead.
Thank you, operator, and thank you everyone for joining us today. On the call, we have Katherine Stueland, Chief Executive Officer, Kevin Feeley, Chief Financial Officer, and Mark Gardner, President. Earlier today, GeneDx released financial results for the third quarter ended September 30, 2026. Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, 2026 guidance, and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, November 9, and we are under no obligation to update. When discussing our results, we refer to non-GAAP measures, which exclude certain items from reported results. Please refer to our third quarter 2026 earnings release and slides available at ir.genedx.com for definitions and reconciliations of non-GAAP measures and additional information regarding our results.
Additionally, please refer to our most recent annual and quarterly filings with the SEC for a discussion of factors that could cause actual results to materially differ from forward-looking statements. With that, I'll turn the call over to Catherine.
Thanks, Sabrina, and good afternoon, everyone. Our Q3 results reflect profitable execution in a growing market. As we first shared in May, we've organized our business around three key imperatives, and in Q3, we made concerted progress on each of them. First and foremost, optimizing unit economics, second, growing utilization, and third, delivering leading products at unmatched scale, all while managing capital responsibly. Today, I'll discuss the highlights of our quarter. Mark will provide a deeper dive on our RCM and commercial initiatives, and Kevin will walk us through the financials. In the third quarter, we reported $123.1 million in total revenue, expanded adjusted gross margin to 72%, generated adjusted net income of $8.6 million, and resulted over 32,100 exome and genome tests. In Q2, we shared that RCM was our number one priority, and we're pleased with the progress we saw here.
Our average reimbursement rate increased approximately 5% sequentially, reflecting both improved genome collections and mix shift into our exome line. As we prioritize profitable growth, we are raising gross margin and net income guidance and reaffirming our full-year total revenue guidance. To that end, in Q3, we aligned genome testing workflows to collect more payer-required documentation before testing begins in the lab. We evaluated the potential effects on ARR, volume, and total revenue and deliberately prioritized a more sustainable path to payment, leading to a sequential step-up in ARR. As we implement these processes and educate clinicians on payer requirements, we are adjusting our volume expectations to give these workflows more time to mature. As a market leader, we are building a better model, one that prioritizes profitable growth, thus enabling us to reinvest into our patients, our products, and our operations in a self-sustaining way.
Part of that model is working closely with payers and governments to ensure equitable, sustainable access to whole exome and genome testing. To support those efforts, I am excited to welcome Nicole Maassen as Chief Patient Access Officer. Nicole was a pivotal force in transforming the market access strategy during her time at Exact Sciences, and as part of our team, she will advance our payer partnerships, build upon our government relations efforts, and help translate positive coverage policies into timely access for children who need testing. Demand is strong. We saw growth across all markets in Q3 as clinicians continue to choose GeneDx for our reliability, quality, and customer experience. This quarter, we made genomic testing easier to adopt with new ordering features, simplified reports, and post-test guides. These enhancements, together with expanded EHR capabilities, support broader adoption of exome and genome across care settings.
We also advanced product innovation in the quarter. We continue to believe genome sequencing will become the standard for diagnosing heritable disease, and our ambition is clear: to consistently deliver the number one genome on the market. We recently announced the inclusion of long-read sequencing as part of our genome portfolio, and we expect to continue rolling out new technologies over the coming quarters. Our underlying data asset, GeneDx Infinity™, underpins many of our competitive advantages in the exome and genome testing markets, but its value also extends beyond our core diagnostics business. Our biopharma and data business grew for the second consecutive quarter, with Mirum Pharmaceuticals and Beren Therapeutics joining our portfolio of sponsored testing partners. In tandem, we are seeing increasing interest from AI and ML and technology players in how our data can advance drug discovery and precision medicine. This is our long-term value proposition coming to life.
As we diagnose more patients, we improve our interpretation capabilities, turn diagnoses into therapeutic breakthroughs, and unlock new avenues for growth and patient impact. With that, I will pass the call over to Mark.
Thank you, Catherine, and good afternoon, everyone. Our remarks today will focus on collections and commercial execution. A genetic test that ends the diagnostic odyssey has real value, and we're intent on getting paid for the value we deliver. Sadly, it has been a common practice of the lab services industry to perform testing in as frictionless a way as possible, to grow volume without regard for whether a test will be paid for or not. We are committed to defending this value for the long term. Our commitments to our patients, clinicians, and shareholders are too important to perpetuate these volume-at-all-cost tactics, particularly because we're in the early stages of penetrating this growing market. The opportunity I saw when I joined GeneDx remains clear. We have strong demand and differentiated clinical capabilities.
Now we must match those strengths with more consistent operational execution to convert unexplained symptoms into orders more consistently, move orders into actionable reports more efficiently, and turn reports into reimbursement more effectively. We started a multi-year revenue cycle transformation. We're in the early stages, but we improved all three of the key metrics that we shared last quarter. Kevin will walk through those details in a moment, but we expect most improvements to impact 2027 and beyond as we continue to tackle our list of RCM initiatives and progress towards collection rates in line with industry norms. We deeply interrogated the root causes of our exome and genome denials, and we found that 62% of them were administrative and procedural in nature. These are addressable with time, effort, and execution, and this is where our team is dedicating most of our immediate efforts.
The remaining 38% relate to subjective clinical necessity disputes or to patients who are not covered by payor policies, and we'll address this group over time. One of the most impactful actions we can take to improve our collection rate is to collect better documentation upfront. As Catherine shared, in Q3, we aligned genome testing workflows to collect more payor-required documentation before testing begins in the lab. Collecting documentation upfront can extend the time between accession and the start of testing, as indicated by accessions growing 28%, while reported volume grew 25% in the quarter. That friction resulted in higher rates of order cancellations, downgrades, and delayed starts.
While that creates a near-term headwind to reported volume, we believe that this is the right approach to support durable revenue growth and expect these requirements to become easier for clinicians to navigate as we implement additional AI and technology tools into our RCM processes. Next, let me speak to how our commercial strategy is enabling us to keep driving demand across core and emerging call points. Our core markets of geneticists and pediatric neurologists delivered strong growth in the quarter, primarily through increased productivity per clinician. We remain the market leader in these segments, and we continue to invest significantly in product development, key opinion leader collaborations, and electronic medical record connectivity to deepen our relationships with these customers. In our emerging markets, we are seeing our commercial investments from early in the year come to fruition.
Importantly, the general pediatrician segment is poised to drive greater unit volume growth in 2027 than all other segments. The GenPeds team entered the field in February, and following two quarters of ramp-up, they're already paying for themselves. Clinicians are placing repeat orders and sharing positive feedback on our enhanced customer ordering experience, and both of these give us confidence moving forward. Lastly, I want to go deeper on something Catherine already referenced, which is the value of GeneDx Infinity™ for building durable competitive differentiation. Many rare pediatric diseases are caused by de novo variants, which arise in the child and are not inherited from either parent. These variants are often seen in only a handful of patients worldwide, and they rarely appear in published literature.
The only way to interpret them is with experience, and GeneDx has sequenced more of these variants than anyone else by an order of magnitude. As we add technologies like long-read sequencing to our portfolio, we can both measure more variants but also expertly match one patient's genetic and clinical profile with another's, thus confirming a genetic diagnosis. That matching exercise is unique, it is cumulative, and it compounds over time. I'll now pass it to Kevin to walk through our financial results.
Thanks, Mark, and good afternoon, everyone. Third quarter 2026 total revenues were $123.1 million, inclusive of $110.4 million of exome genome revenues, which is up $10 million sequentially. This sequential growth is the right frame for evaluating our trajectory, with continued growth and financial improvement. Adjusted gross margin expanded from 69% in Q1 to 70% in Q2 and 72% in Q3, and adjusted net income improved from an $8.2 million loss in Q1 to near break-even in Q2 to $8.6 million this quarter, two consecutive quarters of improvement with more to come. Our blended average reimbursement rate in the third quarter was $3,436, up 5% from $3,258 in the second quarter. We're guiding to another step up in Q4, and we believe the trajectory continues from there as our revenue cycle work matures.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
